Figure 3.

Overview of future strategies for developing next generation immune cell therapy from human pluripotent stem cells. By deploying CAR and clustered regularly interspaced short palindromic repeats (CRISPR/Cas9 technologies, human pluripotent stem cells can be engineered to knockout the genes related to immune rejection, cytokine release syndrome, or to express fourth generation CAR, which can be utilized for precise anti-tumor activity and safety. The engineered human pluripotent stem cells can be clonally selected and expanded. The clonally expanded cells differentiated to immune cells for the therapy. This approach can generate next generation immune cells, which can pave a new way for developing immune cell therapy with off-the shelf, increased potency, increased cost-effectiveness, and an increase in anti-tumor activity precision.